Biomarker & Intervention Discovery

Ischemic Heart Disease / Coronary Artery Disease

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

Disease Overview

Spontaneous remission
Not established
Best-intervention remission
Gap size
Primary barrier
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

ACE 229AGTR1 249CRP 8F2 238IL6 173ITGB3 15LDLR 48NOS3 0PCSK9 170
Therapeutic Agent Effect Direction Evidence Tier Potency Source
SALVIANOLIC ACID B ? unclear Mechanistic
CANDOXATRIL ? unclear Mechanistic
CILAZAPRIL inhibits Mechanistic
TP0556351 inhibits Mechanistic
PRAVASTATIN SODIUM ? unclear Mechanistic
SILDENAFIL ? unclear Mechanistic
GEMFIBROZIL ? unclear Mechanistic
RESCINNAMINE ? unclear Mechanistic
SPIRAPRIL ? unclear Mechanistic
INDOMETHACIN ? unclear Mechanistic
HYDROCHLOROTHIAZIDE ? unclear Mechanistic
ARGIPRESSIN ? unclear Mechanistic
METOPROLOL ? unclear Mechanistic
DELAPRIL inhibits Mechanistic
ACETYLCHOLINE ? unclear Mechanistic
THERAPEUTIC GLUCOCORTICOID ? unclear Mechanistic
IMIDAPRIL inhibits Mechanistic
MALATHION inhibits Mechanistic
MOEXIPRIL ? unclear Mechanistic 56.0 nM (IC50)
VORINOSTAT ? unclear Mechanistic
ILEPATRIL inhibits Mechanistic
RXP470.1 inhibits Mechanistic
CGS-27023A ? unclear Mechanistic
NITROPRUSSIDE ? unclear Mechanistic
ENALAPRILAT ANHYDROUS inhibits Mechanistic 1.2 nM (IC50)
TORSEMIDE ? unclear Mechanistic
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic
FOSINOPRIL ? unclear Mechanistic
FUROSEMIDE ? unclear Mechanistic
TEMOCAPRIL HYDROCHLORIDE ? unclear Mechanistic
BENAZEPRIL HYDROCHLORIDE inhibits Mechanistic
CARBARIL inhibits Mechanistic
BUPROPION HYDROCHLORIDE ? unclear Mechanistic
QUINAPRIL ? unclear Mechanistic 8.3 nM (IC50)
COMPOUND 1 [PMID: 24900526] inhibits Mechanistic
COMPOUND 20 [PMID: 22153340] inhibits Mechanistic
BUMETANIDE ? unclear Mechanistic
GALLOPAMIL ? unclear Mechanistic
FLUOXETINE HYDROCHLORIDE ? unclear Mechanistic
AZD6605 inhibits Mechanistic

Showing top 40 of 229 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CANDESARTAN CILEXETIL inhibits Mechanistic
CHEMBL:CHEMBL586135 ? unclear Mechanistic
VALSARTAN inhibits Mechanistic 4700.0 nM (Ki)
EPROSARTAN MESYLATE inhibits Mechanistic
FIMASARTAN inhibits Mechanistic
ASCORBIC ACID ? unclear Mechanistic
OLMESARTAN MEDOXOMIL inhibits Mechanistic
AZILSARTAN MEDOXOMIL inhibits Mechanistic
THERAPEUTIC ANDROSTANOLONE ? unclear Mechanistic
CHEMBL:CHEMBL347610 ? unclear Mechanistic
CHEMBL:CHEMBL421088 ? unclear Mechanistic
LOSARTAN POTASSIUM inhibits Mechanistic 5.5 nM (IC50)
CHEMBL:CHEMBL1492017 ? unclear Mechanistic
SPARSENTAN inhibits Mechanistic
SODIUM CHLORIDE ? unclear Mechanistic
CHEMBL:CHEMBL261693 ? unclear Mechanistic
CHEMBL:CHEMBL1972216 ? unclear Mechanistic
EPROSARTAN ? unclear Mechanistic 7.3 nM (IC50)
C-FOS ANTISENSE ? unclear Mechanistic
SARALASIN ACETATE inhibits Mechanistic
IRBESARTAN inhibits Mechanistic 1.1 nM (Ki)
DISULFIRAM ? unclear Mechanistic
SAPRISARTAN ? unclear Mechanistic
H2O2 ? unclear Mechanistic
CHEMBL:CHEMBL591834 ? unclear Mechanistic
CAPTOPRIL ? unclear Mechanistic
ANGIOTENSIN II ? unclear Mechanistic
CHEMBL:CHEMBL400912 ? unclear Mechanistic
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic
IDOXIFENE ? unclear Mechanistic
CHEMBL:CHEMBL528694 ? unclear Mechanistic
IL-6 ? unclear Mechanistic
ANGIOTENSIN II ACETATE activates Mechanistic
LEVODOPA ? unclear Mechanistic
GAMMA-INTERFERON ? unclear Mechanistic
AZILSARTAN KAMEDOXOMIL inhibits Mechanistic
HYDROCHLOROTHIAZIDE ? unclear Mechanistic
CHEMBL:CHEMBL1445650 ? unclear Mechanistic
MUSCLE RELAXANT ? unclear Mechanistic
CL-329167 ? unclear Mechanistic

Showing top 40 of 249 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
JNJ1661010 inhibits Mechanistic
ADALIMUMAB ? unclear Mechanistic
LY2077855 inhibits Mechanistic
OL135 inhibits Mechanistic
WARFARIN ? unclear Mechanistic
ASP8477 inhibits Mechanistic
URB597 inhibits Mechanistic
ROSUVASTATIN ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
DESIRUDIN inhibits Mechanistic
BIVALIRUDIN inhibits Mechanistic
TAMOXIFEN ? unclear Mechanistic
PEGMUSIRUDIN ? unclear Mechanistic
FLOVAGATRAN ? unclear Mechanistic
ANISINDIONE ? unclear Mechanistic
HEPARIN ? unclear Mechanistic
CATECHIN ? unclear Mechanistic
DABIGATRAN inhibits Mechanistic
DABIGATRAN ETEXILATE MESYLATE inhibits Mechanistic
QUERCETIN ? unclear Mechanistic
ODIPARCIL ? unclear Mechanistic
DPOC-4088 ? unclear Mechanistic
LUSUTROMBOPAG ? unclear Mechanistic
ICHORCUMAB inhibits Mechanistic
PYRIDOXAL PHOSPHATE ANHYDROUS ? unclear Mechanistic
BORTEZOMIB ? unclear Mechanistic 13000.0 nM (Ki)
ANTITHROMBIN ALFA inhibits Mechanistic
SR-123781A ? unclear Mechanistic
ENOXAPARIN SODIUM ? unclear Mechanistic
CYANIDIN ? unclear Mechanistic
CHEMBL:CHEMBL586628 ? unclear Mechanistic
AZD-8165 ? unclear Mechanistic
STAUROSPORINE inhibits Mechanistic
AVATROMBOPAG ? unclear Mechanistic
HIRUDIN ? unclear Mechanistic
CYANIN ? unclear Mechanistic
COMPOUND 2C [PMID: 24900538] inhibits Mechanistic
SILIBININ ? unclear Mechanistic
EP-217609 ? unclear Mechanistic
APRAMIDE A ? unclear Mechanistic
EPICATECHIN ? unclear Mechanistic
ARGATROBAN inhibits Mechanistic
MELAGATRAN ? unclear Mechanistic 4700.0 nM (IC50)
ATECEGATRAN METOXIL inhibits Mechanistic
ASPIRIN TRELAMINE ? unclear Mechanistic
VITAMIN K3 ? unclear Mechanistic
XIMELAGATRAN inhibits Mechanistic
CHEMBL:CHEMBL1083499 ? unclear Mechanistic
DABIGATRAN ETEXILATE ? unclear Mechanistic

Showing top 40 of 238 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CISPLATIN ? unclear Mechanistic
ZILTIVEKIMAB ~ modulates Mechanistic
CHINESE HERBS ? unclear Mechanistic
PF-04236921 inhibits Mechanistic
MRA 003 US inhibits Mechanistic
SIGNAL TRANSDUCTION INHIBITOR ? unclear Mechanistic
BINETRAKIN ? unclear Mechanistic
IBUDILAST ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
SILTUXIMAB inhibits Mechanistic
METRONIDAZOLE ? unclear Mechanistic
CLAZAKIZUMAB inhibits Mechanistic
GALLIUM NITRATE ? unclear Mechanistic
INTERFERON ALFA-2B ? unclear Mechanistic
DULOXETINE HYDROCHLORIDE ? unclear Mechanistic
MEDI-5117 inhibits Mechanistic
GEMFIBROZIL ? unclear Mechanistic
BIAFINE CREAM ? unclear Mechanistic
ETANERCEPT ? unclear Mechanistic
ELSILIMOMAB inhibits Mechanistic
SAQUINAVIR ? unclear Mechanistic
INFLIXIMAB ? unclear Mechanistic
LINEZOLID ? unclear Mechanistic
IFOSFAMIDE ? unclear Mechanistic
OLOKIZUMAB inhibits Mechanistic
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic
SELENIUM ? unclear Mechanistic
SIRUKUMAB inhibits Mechanistic
PEGINTERFERON ALFA-2B ? unclear Mechanistic
ECHINACEA PREPARATION ? unclear Mechanistic
ENZYME INHIBITOR ? unclear Mechanistic
FENOFIBRATE MICRONIZED ? unclear Mechanistic
VITAMIN K ? unclear Mechanistic
PEGINTERFERON ALFA-2A ? unclear Mechanistic
RIBAVIRIN ? unclear Mechanistic
VITAMIN A PALMITATE ? unclear Mechanistic
ARSENIC TRIOXIDE ? unclear Mechanistic
DIHYDROSPHINGOSINE ? unclear Mechanistic
LEVOFLOXACIN ANHYDROUS ? unclear Mechanistic

Showing top 40 of 173 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
EPTIFIBATIDE inhibits Mechanistic
ATN-161 inhibits Mechanistic
ABCIXIMAB inhibits Mechanistic
CYPATE ? unclear Mechanistic
INTETUMUMAB inhibits Mechanistic
INTEGRIN RECEPTOR ANTAGONIST GLPG0187 ? unclear Mechanistic
ZALUNFIBAN inhibits Mechanistic
CILENGITIDE inhibits Mechanistic
ANTI-THYMOCYTE GLOBULIN ? unclear Mechanistic
TIROFIBAN HYDROCHLORIDE inhibits Mechanistic
ABITUZUMAB inhibits Mechanistic
TIROFIBAN ? unclear Mechanistic
GANTOFIBAN ? unclear Mechanistic
ETARACIZUMAB inhibits Mechanistic
TADOCIZUMAB inhibits Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic
GLUCAGON (RDNA) ? unclear Mechanistic
ATENOLOL ? unclear Mechanistic
VITAMIN A ? unclear Mechanistic
COLESTIPOL HYDROCHLORIDE ? unclear Mechanistic
HEPARIN CALCIUM ? unclear Mechanistic
CHEMBL:CHEMBL233611 ? unclear Mechanistic
TRIBUTYRIN ? unclear Mechanistic
RECOMBINANT TRANSFORMING GROWTH FACTOR ? unclear Mechanistic
CHOLESTYRAMINE RESIN ? unclear Mechanistic
GEMFIBROZIL ? unclear Mechanistic
EPOETIN ALFA ? unclear Mechanistic
TETRACYCLINE ? unclear Mechanistic
HALOPERIDOL DECANOATE ? unclear Mechanistic
MIPOMERSEN ? unclear Mechanistic
PHYTOESTROGEN ? unclear Mechanistic
ANTIVIRAL AGENT ? unclear Mechanistic
FAT EMULSION ? unclear Mechanistic
VERAPAMIL ? unclear Mechanistic
LOMITAPIDE MESYLATE ? unclear Mechanistic
SOY PROTEIN ISOLATE ? unclear Mechanistic
ANTIBIOTIC ? unclear Mechanistic
BUTYRIC ACID ? unclear Mechanistic
ACTH ? unclear Mechanistic
ALIROCUMAB ? unclear Mechanistic
INCLISIRAN ? unclear Mechanistic
LOVASTATIN ? unclear Mechanistic
ACETYLCYSTEINE ? unclear Mechanistic
ROSUVASTATIN ? unclear Mechanistic
PRAVASTATIN SODIUM ? unclear Mechanistic
EVINACUMAB ? unclear Mechanistic
CHEMBL114890 activates Mechanistic 700.0 nM (EC50)
CHEMBL114705 activates Mechanistic 1200.0 nM (EC50)
CHEMBL115304 activates Mechanistic 1300.0 nM (EC50)
CHEMBL324616 activates Mechanistic 700.0 nM (EC50)
CHEMBL115205 activates Mechanistic 4000.0 nM (EC50)
CHEMBL112449 activates Mechanistic 1000.0 nM (EC50)
CHEMBL419400 activates Mechanistic 7000.0 nM (EC50)
CHEMBL419763 activates Mechanistic 1700.0 nM (EC50)
CHEMBL419042 activates Mechanistic 2000.0 nM (EC50)

Showing top 40 of 48 agents ranked by evidence tier.

Pipeline results not yet available for this target. Run the pipeline to populate.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
ALIROCUMAB inhibits Mechanistic
ONGERICIMAB inhibits Mechanistic
TAFOLECIMAB inhibits Mechanistic
LOMITAPIDE MESYLATE ? unclear Mechanistic
EVOLOCUMAB inhibits Mechanistic
RG-7652 inhibits Mechanistic
BOCOCIZUMAB inhibits Mechanistic
FROVOCIMAB ? unclear Mechanistic
RALPANCIZUMAB inhibits Mechanistic
LERODALCIBEP inhibits Mechanistic
INCLISIRAN ? unclear Mechanistic
INCLISIRAN SODIUM ? unclear Mechanistic
DIPHENYL BORINIC ACID inhibits Mechanistic 30000.0 nM (Ki)
PHENYL BUTYL BORINIC ACID inhibits Mechanistic 1000.0 nM (Ki)
CHEMBL4107804 inhibits Mechanistic 3200.0 nM (IC50)
CHEMBL4107907 inhibits Mechanistic 1700.0 nM (IC50)
CHEMBL4114159 inhibits Mechanistic 800.0 nM (IC50)
CHEMBL4108338 inhibits Mechanistic 1500.0 nM (IC50)
CHEMBL4107714 inhibits Mechanistic 1500.0 nM (IC50)
CHEMBL4110311 inhibits Mechanistic 9500.0 nM (IC50)
CHEMBL4107559 inhibits Mechanistic 1800.0 nM (IC50)
CHEMBL4114106 inhibits Mechanistic 1500.0 nM (IC50)
CHEMBL4109097 inhibits Mechanistic 11700.0 nM (IC50)
CHEMBL4108330 inhibits Mechanistic 2300.0 nM (IC50)
CHEMBL4109114 inhibits Mechanistic 4500.0 nM (IC50)
CHEMBL3961039 inhibits Mechanistic 7300.0 nM (IC50)
CHEMBL4112247 inhibits Mechanistic 10700.0 nM (IC50)
CHEMBL4109308 inhibits Mechanistic 800.0 nM (IC50)
CHEMBL4109014 inhibits Mechanistic 11820.0 nM (IC50)
CHEMBL4108567 inhibits Mechanistic 3800.0 nM (IC50)
CHEMBL4111131 inhibits Mechanistic 18000.0 nM (IC50)
CHEMBL4115372 inhibits Mechanistic 1700.0 nM (IC50)
CHEMBL4106481 inhibits Mechanistic 3050.0 nM (IC50)
CHEMBL4108186 inhibits Mechanistic 5610.0 nM (IC50)
CHEMBL4115360 inhibits Mechanistic 5800.0 nM (IC50)
CHEMBL4114503 inhibits Mechanistic 25300.0 nM (IC50)
CHEMBL4108540 inhibits Mechanistic 2970.0 nM (IC50)
CHEMBL4109409 inhibits Mechanistic 5750.0 nM (IC50)
CHEMBL4109932 inhibits Mechanistic 14300.0 nM (IC50)
CHEMBL4106569 inhibits Mechanistic 16800.0 nM (IC50)

Showing top 40 of 170 agents ranked by evidence tier.


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.

NCT05491200 Phase: PHASE4 Started: 2022-07-22

The study is a multi-centre, Open-label, Randomized Controlled, 1:1 trial comparing Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus standard DAPT regimen in STEMI patients in terms of safety and efficacy endpoints. In the subgroup of STEMI patients with MVD, a sub-r...

NCT06939738 Phase: N/A Started: 2025-04-01

The ASSIST clinical study is an observational, multicenter study to assess the performance of a cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, developed to detect Acute Myocardial Infarction (AMI). The main objectives are to compare Willem™ performance to detec...

NCT05699005 Phase: PHASE1 Started: 2023-09-18

This multicenter randomized controlled trial compare two transfusion strategies of red blood cells transfusion in patients supported by veno-arterial extracorporeal membrane oxygenation for refractory cardiogenic shock. An individualized transfusion strategy based on ScVO2 level, is compared to a c...

NCT06909565 Phase: PHASE4 Started: 2025-07-23

V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin th...

NCT05157932 Phase: NA Started: 2022-07-08

The objectives of this pilot RCT are to examine if the Talk Test is an effective and safe tool as compared with CPET for exercise prescription in patients who have undergone CABG or PCI and enrolled in a home-based CR program with virtual exercise training monitoring.

NCT05434117 Phase: NA Started: 2022-12-09

Coronary revascularization, such as heart bypass surgery (CABG) and percutaneous coronary intervention (PCI \[inserting a stent to open up blood vessels\]) improve survival for people with coronary artery disease. Yet, many patients suffer from poor physical and mental health after coronary revascul...

NCT07362446 Phase: PHASE2 Started: 2026-04-22

This study is open to adults with ST elevation myocardial infarction (heart attack) undergoing primary percutaneous coronary intervention (PCI). The purpose of this study is to determine whether a medicine called Xolatryp is safe and effective in improving cardiac outcomes. One dose of Xolatryp will...

NCT06186102 Phase: PHASE2 Started: 2024-01-01

The present study is testing spermidine treatment in elderly patients with coronary artery disease. The study is a randomized, double-blind, placebo-controlled, two-armed, parallel-group, single centre, clinical study.

NCT07676656 Phase: N/A Started: 2025-02-28

aim of this study was to evaluate the relationship between multiple conventional and novel anthropometric measurements and hypertension in patients presenting to the ED with ACS and whether anthropometric indices differ according to admission BP status and evaluated the relationship between regional...

NCT00552591 Phase: NA Started: 2007-09

Background: Family members (spouses, siblings, offspring) of patients with coronary heart disease (CHD) may themselves be at increased risk for developing CHD for genetic, biochemical and/or behavioural reasons. Targeted approaches aimed at family members of those with established CHD may be a cost-...

NCT01621594 Phase: NA Started: 2012-06-21

Title: Evaluating New Radiation Techniques for Cardiovascular Imaging Background: Cardiac CT angiography is associated with radiation exposure. Different methods of creating CT pictures have been developed to reduce the radiation dose to the subject. The purpose of this research study is to learn ...

NCT00265525 Phase: NA Started: 2004-11

A randomized control trial (RCT) is planned to evaluate a web-based intervention (CardioFit) against usual care in increasing physical activity levels in patients with Coronary Artery Disease (CAD). We hypothesize that compared to usual care, participants in CardioFit will; a) have increased physica...

NCT06813339 Phase: EARLY_PHASE1 Started: 2025-02-25

The goal of this clinical trial is to learn if UDP-003 is safe in healthy human participants and patients, assess the pharmacokinetics (PK)/pharmacodynamics (PD) of UDP-003 in healthy human participants and patients and its potential efficacy in patients. Researchers will compare UDP-003 to a place...

NCT00449852 Phase: NA Started: 2006-07

A randomized control trial is planned to evaluate an interactive voice response (IVR) mediated follow-up and triage system, against usual care, to help smokers hospitalized with Coronary Heart Disease (CHD) to quit smoking. The investigators hypothesize that compared to usual care, participants in t...

NCT01186133 Phase: N/A Started: 2009-01

The objective of this study is to evaluate effectiveness and safety of the new drug-eluting stent (DES), as compared with the first-,second-,third-, and fourth-generation DES, in the "real world" daily practice.


Agents Found By Disease-Level Search

Searched directly from “Ischemic Heart Disease / Coronary Artery Disease” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 9-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.